SEARCH

SEARCH BY CITATION

References

  • Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 11141124.
  • Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M.-F., Dennis, M., Pallis, M., Russell, N., Hills, R. & Wheatley, K. (2009) The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia: the results of the LRF AML14 trial. British Journal of Haematology, doi: DOI: 10.1111/j.1365-2141.2009.07604.x
  • Cartwright, R.A., Alexandre, F.E. & McKinney, P.A. (1990) Leukaemia and Lymphoma: an Atlas of Distribution within Areas of England and Wales 1984–88. Leukaemia Research Fund, London.
  • Gibson, B.E.S., Wheatley, K., Hann, I., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S.N. & Harrison, C.J. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19, 21302138.
  • Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M. & Clark, R.E. (2001) Attempts to improve treatment outcomes in Acute Myeloid Leukaemia in Older Patients: the results of the UK Medical Research Council AML11 Trial. Blood, 98, 13021311.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML10 trial. Blood, 92, 23222333.
  • Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K. & Goldstone, A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1605 patients entered into the MRC AML11 trial. Blood, 98, 13121320.
  • Hughes, M.D. (1993) Regression dilution in the proportional hazards model. Biometrics, 49, 10561066.
  • Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia adds important prognostic information to cyctogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the UK MRC AML10 and 12 trials. Blood, 98, 17521759.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.-M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 33233329.
  • Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, F.R. & Willman, C.L. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 10861099.
  • Lowenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M., Solbu, G. & Suciu, S. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology, 7, 12681274.
  • Malfuson, J.-V., Etienne, A., Turlure, P., De Revel, T., Thomas, X., Contentin, N., Terré, C., Rigaudeau, S., Bordessoule, D., Vey, N., Gardin, C. & Dombret, H. (2008) Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica, 93, 18061813.
  • Mistry, A.R., Wessel-Pedersen, E., Solomon, E. & Grimwade, D. (2003) The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Reviews, 17, 7197.
  • Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prise, P.Y., Tertian, G., Desablens, B., Henry-Amar, M. & Degos, L. (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology, 8, 272279.
  • Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K.H., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML10 trial. British Journal of Haematology, 107, 6979.